Man in lab with beaker

An industry-leading uro-oncology pipeline

Our investigational product candidates have the potential to advance the treatment of a number
of urological and uro-oncological conditions.

Our current pipeline

Our current pipeline

Urology Immuno- uro-oncology Uro-oncology Overactive bladder (OAB) BOTOX ® /RTGel TM reverse- thermal hydrogel High-grade non-muscle invasive bladder cancer (NMIBC) UGN-201 Low-grade non-muscle invasive bladder cancer (NMIBC) UGN-102 Low-grade upper tract urothelial carcinoma (UTUC) UGN-101 (orphan) REGISTRATION PHASE 3 PHASE 2 PHASE 1 NONCLINICAL PROGRAM CATEGORY

*Licensed to Allergan. The safety and efficacy of the above product candidates for the specified conditions have not been established.
BOTOX is a registered trademark of Allergan plc.

PHASE 2 BOTOX ® /RTGel TM reverse-thermal hydrogel Overactive bladder (OAB) Urology NON- CLINICAL UGN-201High-grade non-muscleinvasive bladder cancer (NMIBC) Immuno-uro-oncology PHASE 2 UGN-102Low-grade non-muscleinvasive bladder cancer (NMIBC) REGISTRATION UGN-101 (orphan)Low-grade upper tract urothelial carcinoma (UTUC) Uro-oncology

*Licensed to Allergan. The safety and efficacy of the above product candidates for the specified conditions have not been established.
BOTOX is a registered trademark of Allergan plc.